Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow SNN
Smith & Nephew SNATS, Inc. (SNN) P/E ratio
As of 16 October 2026, Smith & Nephew SNATS, Inc. (SNN) trades at a P/E ratio of 35.4×. Over the past ten years it has ranged from 18.2× (September 2022) to 47.2× (September 2025); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 40.0× | 33.48% |
| FY2024 | 30.0× | (8.45%) |
| FY2023 | 32.7× | 2.42% |
| FY2022 | 32.0× | 3.67% |
| FY2021 | 30.8× | (11.84%) |
| FY2020 | 35.0× | 7.59% |
| FY2019 | 32.5× | 6.52% |
| FY2018 | 30.5× | (1.57%) |
| FY2017 | 31.0× | 16.37% |
| FY2016 | 26.6× | (15.76%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 39.3× | 23.02% |
| Dec 2022 | 32.0× | 37.89% |
| Jun 2022 | 23.2× | (24.82%) |
| Dec 2021 | 30.8× | (21.92%) |
| 6 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| GMED Globus Medical, Inc. compare | 19.3× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 23.0× |
| PODD Insulet Corporation compare | 26.4× |
| SNN Smith & Nephew SNATS, Inc. | 35.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 42.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 43.7× |
| PEN Penumbra, Inc. compare | 78.4× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)